An EXELent Drug Deal

With less than three weeks left in the year, Exelixis (Nasdaq: EXEL  ) cut it close, but management got the job done.

The company had guided to have at least $200 million in the bank at the end of 2008, so it needed to make at least one more licensing deal for its plethora of unpartnered drugs. No problem; today it picked up $195 million in cash in a deal with Bristol-Myers Squibb (NYSE: BMY  ) .

The deal doesn't come as a big surprise to me. Management tipped its hand a few weeks ago when it agreed to spend some of its cash to co-develop a drug with Bristol-Myers as part of an established partnership.

The new deal with Bristol-Myers involves Exelixis' phase 3 thyroid cancer drug XL184 -- the same drug that GlaxoSmithKline (NYSE: GSK  ) turned down in October. As I suggested at the time, Glaxo's decision was likely a business one and not based on the likelihood of clinical success, since Bristol-Myers agreed to license the drug and Exelixis has decided to spend some of its cash to co-develop the drug. Exelixis will share profits in the U.S., and potentially get $150 million in milestone payments and double-digit royalties should the drug get approved outside the U.S.

Bristol-Myers also gets phase 1 cancer drug XL281 as part of the deal. The pharma giant will take over development of the drug and Exelixis could get milestone payments of up to $465 million as the drug progresses through the clinic and becomes a commercial success. Exelixis is also entitled to double-digit royalties on worldwide sales of XL281.

This deal puts the Motley Fool Rule Breakers pick in pretty good shape. Between the cash it received this year, the $45 million it'll get next year as part of this deal, and potential milestone payments from partners Glaxo, Wyeth (NYSE: WYE  ) , Genentech (NYSE: DNA  ) , and Daiichi Sankyo, Exelixis is looking good for the next couple of years. Hopefully by then the market will have rebounded and the drugmaker can use the usual method of carrying out secondary offerings to gain any additional cash it might need.

More Foolishness on drugmakers' need for cash:

Find out why The Motley Fool picked Exelixis for the high-growth Rule Breakers newsletter by grabbing a free 30-day trial. You'll get access to all our back issues and the most recent picks.  

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. GlaxoSmithKline is a Motley Fool Income Investor selection. The Fool owns shares of Exelixis. The Fool's disclosure policy likes its marshmallows lightly toasted.


Read/Post Comments (0) | Recommend This Article (14)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 794082, ~/Articles/ArticleHandler.aspx, 10/21/2014 5:55:46 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement